MarketPulse

FDA deficiencies

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Aquestive Stock Crashes 37% After FDA Rejection; Class Action Deadline Set for May 4

Class action lawsuit filed against Aquestive Therapeutics after company failed to disclose FDA deficiencies blocking Anaphylm approval, triggering 37% stock decline.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Gross Law Firm

Aquestive Therapeutics Faces Securities Lawsuit After Anaphylm FDA Setback Triggers 37% Stock Plunge

Aquestive Therapeutics faces securities lawsuit after FDA Anaphylm deficiency notice triggers 37% stock decline from $6.21 to $3.91 on January 9, 2026.
AQSTstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Aquestive Faces Class Action Over Anaphylm FDA Approval Misstatements

Aquestive Therapeutics faces class action lawsuit alleging FDA approval misrepresentations for Anaphylm. Stock dropped 37% January 9; lead plaintiff applications due May 4, 2026.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Aquestive Therapeutics Faces FDA Setback on Anaphylm Application; Investor Claims Under Review

Aquestive Therapeutics' stock plunged 40% after FDA cited major deficiencies in its Anaphylm anaphylaxis treatment application. Shareholder lawsuit investigation underway over disclosure adequacy.
AQSTstock declinesecurities investigation